Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 1.00 |
| ▸ | AURKA | O14965 | 10/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 6/20 | 0.47 |
| ▸ | HTR2A | P28223 | 6/20 | 0.47 |
| ▸ | HTR1A | P08908 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5328153 | 0.91 | KDR (1.00) | KDRAURKACDK1DRD2HTR2A | |
| SCHEMBL14468698 | 0.88 | KDR (0.83) | KDRAURKACDK1DRD2HTR2A | |
| SCHEMBL5327067 | 0.86 | KDR (1.00) | KDRAURKACDK1 | |
| SCHEMBL5329621 | 0.86 | KDR (0.85) | KDRAURKACDK1DRD2HTR2A | |
| SCHEMBL5331815 | 0.85 | KDR (1.00) | KDRAURKACDK1 | |
| SCHEMBL5327042 | 0.83 | KDR (1.00) | KDRAURKACDK1DRD2HTR2A | |
| SCHEMBL5314912 | 0.79 | KDR (1.00) | KDRAURKACDK1 | |
| SCHEMBL5312152 | 0.78 | AURKA (1.00) | KDRAURKACDK1 | |
| SCHEMBL5079401 | 0.75 | KDR (0.75) | KDRAURKADRD2 | |
| SCHEMBL15520163 | 0.72 | KDR (0.56) | KDRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | claimed |
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | disclosed |
| WO-2007047646-A2 | SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | MAP3K20, MAP3K3, MAP3K19 | KDR 1627/4885AURKA 669/4885CDK1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.